Italia markets closed
FTSE MIB
35.398,82 -11,31 (-0,03%) Dow Jones
40.003,59 +134,21 (+0,34%) Nasdaq
16.685,97 -12,35 (-0,07%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
80,00 +0,77 (+0,97%) Bitcoin EUR
61.355,42 +1.277,54 (+2,13%)
NBIX Jun 2024 120.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 09:58AM EDT. Mercato aperto.
| Chiusura precedente | 3,4100 |
| Aperto | 3,4100 |
| Denaro | 0,0000 |
| Lettera | 4,8000 |
| Prezzo d'esercizio | 120,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 3,4100 - 3,4100 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 57 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.